Cancer constitutes one of the most urgent global health crises, with over 20 million new cases diagnosed annually worldwide, claiming 10 million lives. This devastating burden disproportionately affects vulnerable populations: 75% of cancer deaths occur in low- and middle-income countries despite these regions having lower reported incidence rates. Lung cancer leads the global toll, representing 12% of all cases but 19% of deaths, followed by breast cancer (12% of cases) and colorectal cancer (9.6%). A stark geographical inequity defines the cancer landscape-while wealthy regions such as North America, Northern Europe and Australia report the highest incidence rates, Africa and Latin America suffer the highest mortality rates. This disparity will intensify dramatically: cancer deaths in low-income countries are projected to surge 155% compared to just 56% in high-income nations by 2050. The financial devastation compounds this crisis, with 56% of patients worldwide facing catastrophic health expenditures extending beyond medical costs to include lost income and reduced productivity. Economic burden varies starkly by wealth: 75% of patients in low-income countries experience financial catastrophe versus 58% in middle-income countries and 26% in high-income nations. However, cancer prevention offers unprecedented opportunities to transform this crisis through interventions we already possess. From largely preventable infectious cancers like stomach and cervical malignancies, to lifestyle-driven epidemics including lung and colorectal cancers, to complex multifactorial diseases like breast cancer. Evidence-based prevention strategies can dramatically reduce suffering while generating massive healthcare savings. Emerging genetic technologies amplify this potential: universal genetic testing and pharmacogenomics now enable identification of high-risk individuals before disease develops, allowing targeted prevention while optimising treatments based on individual genetic These five cancers reveal the multifaceted nature of the global crisis: from largely preventable infectious diseases like stomach and cervical cancer, to lifestyle-driven epidemics like lung and colorectal cancer, to the complex challenge of breast cancer that combines genetic, environmental and social determinants. Each offers distinct prevention opportunities—tobacco control for lung cancer, human papillomavirus vaccination for cervical cancer, Helicobacter pylori treatment for stomach cancer, lifestyle modification for colorectal cancer and early detection plus genetic risk assessment for breast cancer. This statistic represents not just individual tragedy but a broader social disruption as families fragment and communities lose vital members who would have contributed to society during their prime adulthood. Mapping the global cancer landscape: geographic disparities and prevention opportunities With the world’s largest population and the country's rapid population aging, China accounts for 24% of all cancer cases worldwide, ranking 64th out of 185 countries in terms of age-standardized incidence rates. In 2022, there were 4.82 million new cancer cases and 2.57 million deaths. As India's demographic profile shifts from a predominantly reproductive-age population toward middle-aged and geriatric cohorts, the country is projected to experience an unprecedented cancer burden in the coming decades, potentially reaching historic levels. Beyond China and India, stomach cancer reveals Asia's broader regional patterns, with Eastern Asia reporting 520,000 cases—the highest regional burden globally. The numbers tell a compelling story. According to new data in The Cancer Atlas, Fourth Edition (2025), an estimated 50% of cancer deaths worldwide stem from modifiable risk factors that we can control: tobacco and alcohol use, infections, excess body weight, poor diet, physical inactivity, ultraviolet radiation, environmental pollutants and workplace exposures. The tobacco epidemic alone accounts for over 20% of all cancer deaths globally, while infections drive 12% of new diagnoses. Excess body weight has been definitively linked to at least 13 cancer types and is associated with 40% of uterine cancer deaths and 20% of kidney cancer fatalities. These findings underscore nutrition's critical role as a modifiable cancer prevention factor and demand stronger public health strategies to reduce exposure to dietary carcinogens. The economic imperative for prevention interventions The economic case for cancer prevention rivals the health benefits, representing one of modern healthcare's most cost-effective interventions. Cancer screening and early detection deliver extraordinary investment returns through multiple economic mechanisms extending far beyond immediate treatment savings. The convergence of rapidly advancing genetic science with decreasing costs has created an unprecedented opportunity: universal genetic testing and pharmacogenomics could fundamentally transform cancer care from reactive treatment to proactive prevention. While this technology currently flourishes primarily in resource-rich nations, the benefits are so compelling that global adoption appears inevitable as costs plummet and accessibility expands. The genetic reality of cancer has fundamentally dismantled our previous assumptions about hereditary risk. Pharmacogenomics: optimising treatment while minimising harm While genetic testing addresses cancer prevention, pharmacogenomics confronts an equally critical challenge: ensuring that life-saving treatments do not become life-threatening. The fundamental flaw in modern prescribing should surprise no one—humans do not metabolise drugs at the same rate. However, standard drug dosing persists with a traditional ‘one size fits all’ approach, creates a medical lottery where some patients metabolise medications too rapidly to receive any benefit, while others process them so slowly that standard doses become toxic.